免疫介导的检查点抑制剂不良反应:临床经验

European Pharmaceutical Journal Pub Date : 2022-06-18 DOI:10.2478/afpuc-2022-0006

J. Juřica, R. Goněc, Adéla Bartova, J. Gregorová

{"title":"免疫介导的检查点抑制剂不良反应:临床经验","authors":"J. Juřica, R. Goněc, Adéla Bartova, J. Gregorová","doi":"10.2478/afpuc-2022-0006","DOIUrl":null,"url":null,"abstract":"Abstract Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.","PeriodicalId":12070,"journal":{"name":"European Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience\",\"authors\":\"J. Juřica, R. Goněc, Adéla Bartova, J. Gregorová\",\"doi\":\"10.2478/afpuc-2022-0006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.\",\"PeriodicalId\":12070,\"journal\":{\"name\":\"European Pharmaceutical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Pharmaceutical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/afpuc-2022-0006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/afpuc-2022-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

摘要免疫检查点抑制剂（ICIs）的自身免疫不良反应很罕见，但可能危及生命。我们对2011年至2021年Masaryk Memorial癌症研究所（MMCI）ICIs的免疫相关不良反应（irAE）进行了回顾性分析。对648名患者使用ICIs。83名患者（12.8%）出现严重irAE。此外，我们报告了一例使用易普利木单抗和尼沃单抗治疗后出现严重irAE的病例。使用泼尼松、美沙拉秦、奥曲肽、英夫利昔单抗、韦多利珠单抗和霉酚酸酯治疗G4结肠炎，部分缓解。从进一步肿瘤学治疗的角度来看，早期诊断和适当管理irAE是至关重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Abstract Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Pharmaceutical Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： European Pharmaceutical Journal publishes only original articles not previously published and articles that are not being considered or have not been submitted for publication elsewhere. If parts of the results have been published as conference abstract or elsewhere, it should be stated in references. The ethical standards of the Helsinki-Tokio Declaration should be kept. This should be mentioned in the Methods of manuscript. Reviews are published only on request. Authors, whose submitted research work was performed with the support of a company, should indicate this in Conflict of Interest.